% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Fittall:157748,
author = {M. W. Fittall and I. Lyskjaer and P. Ellery and P. Lombard
and J. Ijaz and A.-C. Strobl and D. Oukrif and M. Tarabichi
and M. Sill$^*$ and C. Koelsche and G. Mechtersheimer and J.
Demeulemeester and R. Tirabosco and F. Amary and P. J.
Campbell and S. Pfister$^*$ and D. T. W. Jones$^*$ and N.
Pillay and P. Van Loo and S. Behjati and A. M. Flanagan},
title = {{D}rivers underpinning the malignant transformation of
giant cell tumour of bone.},
journal = {The journal of pathology},
volume = {252},
number = {4},
issn = {1096-9896},
address = {Bognor Regis [u.a.]},
publisher = {Wiley},
reportid = {DKFZ-2020-01785},
pages = {433-440},
year = {2020},
note = {2020 Dec;252(4):433-440},
abstract = {The rare benign giant cell tumour of bone (GCTB) is defined
by an almost unique mutation in the H3.3 family of histone
genes H3-3A or H3-3B, however the same mutation is
occasionally found in primary malignant bone tumours which
share many features with the benign variant. Moreover, lung
metastases can occur despite the absence of malignant
histological features in either the primary or metastatic
lesions. Herein we investigated the genetic events of 17
GCTBs including benign and malignant variants and the
methylation profiles of 122 bone tumour samples including
GCTBs. Benign GCTBs possessed few somatic alterations and no
other known drivers besides the H3.3 mutation, whereas all
malignant tumours harboured at least one additional driver
mutation and exhibited genomic features resembling
osteosarcomas, including high mutational burden, additional
driver event(s) and a high degree of aneuploidy. The H3.3
mutation was found to predate the development of aneuploidy.
In contrast to osteosarcomas, malignant H3.3-mutated tumours
were enriched for a variety of alterations involving TERT,
other than amplification, suggesting telomere dysfunction in
the transformation of benign to malignant GCTB. DNA
sequencing of the benign metastasising GCTB revealed no
additional driver alterations; polyclonal seeding in the
lung was identified, implying that the metastatic lesions
represent an embolic event. Unsupervised clustering of DNA
methylation profiles revealed that malignant H3.3- mutated
tumours are distinct from their benign counterpart, and
other bone tumours. Differential methylation analysis
identified CCND1, encoding cyclin D1, as a plausible cancer
driver gene in these tumours because hypermethylation of the
CCND1 promoter was specific for GCTBs. We report here the
genomic and methylation patterns underlying the rare
clinical phenomena of benign metastasising and malignant
transformation of GCTB and show how the combination of
genomic and epigenomic findings could potentially
distinguish benign from malignant GCTBs, thereby predicting
aggressive behaviour in challenging diagnostic cases. This
article is protected by copyright. All rights reserved.},
cin = {B062 / HD01 / B360},
ddc = {610},
cid = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)B360-20160331},
pnm = {312 - Functional and structural genomics (POF3-312)},
pid = {G:(DE-HGF)POF3-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:32866294},
doi = {10.1002/path.5537},
url = {https://inrepo02.dkfz.de/record/157748},
}